Journal article
Rituximab for the Treatment of Adults with ITP: A Systematic Review.
Abstract
Abstract
Background: Rituximab, a monoclonal anti-CD20 antibody, is a promising therapeutic agent for adults with idiopathic immune thrombocytopenic purpura (ITP).
Authors
Arnold DM; Dentali F; Meyer RM; Crowther MA; Sigouin C; Kelton JG
Journal
Blood, Vol. 106, No. 11,
Publisher
American Society of Hematology
Publication Date
November 16, 2005
DOI
10.1182/blood.v106.11.1241.1241
ISSN
0006-4971